We have seen astonishing results in wound healing, cardiac function recovery nerve repair, disease mitigation and arthritis mitigation and treatment of crippling back pain. Many patients have delayed or avoided joint replacement by having SVF deployments. We have helped patients with Peyronies disease- or penile scarring with no effective therapy. We have provided relief for numerous patients with debilitating autoimmune diseases. The uses and various methods of deploying SVF are continually growing.
Two years ago, with the understanding that it is important to teach our technology, we started training select physicians to use our techniques to isolate SVF and incorporate it in their practices.
We formed a translational research network that includes 65 centers in the Uniter states and facilities as far away as Asia, South Africa , South America and New Zealand . We called the project, cell surgical Network. All network physicians are performing cell surgery using identical protocols that we developed in our centers during the past four years and all are collecting outcomes data in our online advanced database . We have presented out data throughout the world including at the prestigious World Stem Cell Summit in 2013.
SVF deployment is a disruptive technology that allows surgeons to tap the human storehouse of healing cells, taking them from fat and making them “bio-available” for disease mitigation. Many clinicians in the United States and Europe are waiting for the pharma-ceutical industry to provide cell-based therapeutics. But those will come from a laboratory after a prolonged regulatory process. Others have chosen to use procurement and the knowledge that we have accumulated here and overseas to benefit their patients today
As with any new industry, many clinics have entered the fray including some without adequate knowledge and training, but interested in riding the regenerative medicine wave. Their websites are full of testimonials and irresponsible claims. Physicians and consumers need to understand that not all stem cell clinics should be painted with the same broad strokes .
Those committed to data collection ,that emphasize training , and have IRB oversight should set examples for a model of how we can accelerate the quality of regenerative medicine.